The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.
The main questions it aims to answer are:
* Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency? * Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients?
Participants blood will be collected at several time points.
Patients of at least 18 years old,
Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,
The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,
Advanced HCC defined by BCLC stages B and C,
Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)
No personal history of neoplasia in the previous 5 years
No personal history of systemic inflammatory diseases
No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)
University Hospital, Montpellier
Lead sponsor